In January 2014, the company launched the Open Innovation Hub, a venue for presenting Fujifilm Group's fundamental and core technologies and materials, and products and services based on such technologies to external business partners, including companies and research institutes, to initiate “co-creation” of fresh values. In December 2013, the company partnered with the Alzheimer’s Disease Cooperative Study (ADCS), the largest Alzheimer’s disease therapeutic research consortium in the US, to carry out a Phase II clinical trial of the Alzheimer’s disease drug “T-817MA” to accelerate its development in the US. In November 2013, the company established a local subsidiary, Fujifilm Myanmar Limited, in the Republic of the Union of Myanmar.